Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul;267(7):1991-2001.
doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18.

'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

John Vissing  1 , Saiju Jacob  2 , Kenji P Fujita  3   4 , Fanny O'Brien  5 , James F Howard  6 ; REGAIN study group
Collaborators, Affiliations
Clinical Trial

'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

John Vissing et al. J Neurol. 2020 Jul.

Abstract

Background: The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension.

Methods: Attainment of 'minimal symptom expression' was evaluated using patient-reported outcome measures of gMG symptoms [MG activities of daily living scale (MG-ADL), 15-item MG quality of life questionnaire (MG-QOL15)] at the completion of REGAIN and during the open-label extension. 'Minimal symptom expression' was defined as MG-ADL total score of 0-1 or MG-QOL15 total score of 0-3.

Results: At REGAIN week 26, more eculizumab-treated patients achieved 'minimal symptom expression' versus placebo [MG-ADL: 21.4% vs 1.7%; difference 19.8%; 95% confidence interval (CI) 8.5, 31.0; p = 0.0007; MG-QOL15: 16.1% vs 1.7%; difference 14.4%; 95% CI 4.3, 24.6; p = 0.0069]. During the open-label extension, the proportion of patients in the placebo/eculizumab group who achieved 'minimal symptom expression' increased after initiating eculizumab treatment and was sustained through 130 weeks of open-label eculizumab (MG-ADL: 1.7 to 27.8%; MG-QOL15: 1.7 to 19.4%). At extension study week 130, similar proportions of patients in the eculizumab/eculizumab and placebo/eculizumab groups achieved 'minimal symptom expression' (MG-ADL: 22.9% and 27.8%, respectively, p = 0.7861; MG-QOL15: 14.3% and 19.4%, respectively, p = 0.7531). The long-term tolerability of eculizumab was consistent with previous reports.

Conclusions: Patients with AChR+ refractory gMG who receive eculizumab can achieve sustained 'minimal symptom expression' based on patient-reported outcomes. 'Minimal symptom expression' may be a useful tool in measuring therapy effectiveness in gMG.

Trial registration: ClinicalTrials.gov NCT01997229, NCT02301624.

Keywords: Acetylcholine receptor; Eculizumab; Minimal symptom expression; Myasthenia gravis; Refractory.

PubMed Disclaimer

Conflict of interest statement

This work was funded by Alexion Pharmaceuticals. J.V. has received research and travel support, and/or speaker honoraria from Alexion Pharmaceuticals and Sanofi/Genzyme, and has served on advisory boards or as a consultant for Asklepios Biopharmaceuticals, Audentes Therapeutics, Novartis Pharma AG, PTC Therapeutics, Roche, Sanofi/Genzyme, Santhera Pharmaceuticals, Sarepta Therapeutics, and Stealth Biotherapeutics within the past 3 years. S.J. is a member of an international advisory board for Alexion Pharmaceuticals, has been an advisory board member for Alnylam Pharmaceuticals and Argenx BVBA, has received speaker fees from Terumo BCT, and has received research support from the Wellcome Trust Clinical Research Facility and Centre for Rare Diseases at the University Hospitals Birmingham, UK. K.P.F. was employed by and owns stock in Alexion Pharmaceuticals and is employed by Alnylam Pharmaceuticals. F.O’B. is employed by, and owns stock in, Alexion Pharmaceuticals. J.F.H. has received research support from Alexion Pharmaceuticals, argenx BVBA, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Ra Pharmaceuticals; has received honoraria from Alexion Pharmaceuticals; and has received non-financial support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals and Toleranzia.

Figures

Fig. 1
Fig. 1
Patient disposition in REGAIN and the open-label study
Fig. 2
Fig. 2
a Proportions of patients achieving ‘minimal symptom expression’, defined as an MG-ADL total score of 0–1. b Proportions of patients achieving ‘minimal symptom expression’, defined as an MG-QOL15 total score of 0–3. *p < 0.01; **p < 0.001 vs placebo. p values are based on Fisher’s exact test. MG-ADL myasthenia gravis activities of daily living questionnaire, MG-QOL15 15-item myasthenia gravis quality of life questionnaire
See this image and copyright information in PMC

References

    1. Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86:255–260. - PMC - PubMed
    1. Buzzard KA, Meyer NJ, Hardy TA, Riminton DS, Reddel SW. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve. 2015;52:204–210. doi: 10.1002/mus.24536. - DOI - PubMed
    1. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141–149. doi: 10.1002/mus.20950. - DOI - PubMed
    1. Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. 2018;58:99–105. doi: 10.1002/mus.26114. - DOI - PubMed
    1. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305–314. doi: 10.1196/annals.1405.033. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data